104 related articles for article (PubMed ID: 38761670)
1. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
3. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
Schweitzer F; Ladwig A; Opala S; Laurent S; Schroeter M; Goelz S; Fink GR; Wieland U; Silling S; Warnke C
Mult Scler Relat Disord; 2024 Jul; 87():105664. PubMed ID: 38735204
[TBL] [Abstract][Full Text] [Related]
4. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
[TBL] [Abstract][Full Text] [Related]
5. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
[TBL] [Abstract][Full Text] [Related]
6. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
Kolcava J; Hulova M; Benesova Y; Bednarik J; Stourac P
Mult Scler Relat Disord; 2019 May; 30():187-191. PubMed ID: 30785075
[TBL] [Abstract][Full Text] [Related]
7. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
[TBL] [Abstract][Full Text] [Related]
8. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
[TBL] [Abstract][Full Text] [Related]
9. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population.
Correia I; Jesus-Ribeiro J; Batista S; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
J Clin Neurosci; 2017 Nov; 45():257-260. PubMed ID: 28844615
[TBL] [Abstract][Full Text] [Related]
10. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
[TBL] [Abstract][Full Text] [Related]
11. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
12. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
[TBL] [Abstract][Full Text] [Related]
13. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
[TBL] [Abstract][Full Text] [Related]
14. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
[TBL] [Abstract][Full Text] [Related]
15. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
Delbue S; Elia F; Carloni C; Pecchenini V; Franciotta D; Gastaldi M; Colombo E; Signorini L; Carluccio S; Bellizzi A; Bergamaschi R; Ferrante P
J Neurovirol; 2015 Dec; 21(6):645-52. PubMed ID: 25052191
[TBL] [Abstract][Full Text] [Related]
16. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
[TBL] [Abstract][Full Text] [Related]
17. JCV serology in time: 3 years of follow-up.
Cambron M; Hadhoum N; Duhin E; Lacour A; Chouraki A; Vermersch P
Acta Neurol Scand; 2017 Jul; 136(1):54-58. PubMed ID: 27766611
[TBL] [Abstract][Full Text] [Related]
18. Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab.
Sgarlata E; Chisari CG; D'Amico E; Millefiorini E; Patti F
CNS Drugs; 2020 May; 34(5):535-543. PubMed ID: 32221861
[TBL] [Abstract][Full Text] [Related]
19. Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.
Pietropaolo V; Bellizzi A; Anzivino E; Iannetta M; Zingaropoli MA; Rodio DM; Morreale M; Pontecorvo S; Francia A; Vullo V; Palamara AT; Ciardi MR
J Neurovirol; 2015 Dec; 21(6):653-65. PubMed ID: 25930159
[TBL] [Abstract][Full Text] [Related]
20. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]